| Patents for A61K 38 - Medicinal preparations containing peptides (316,240) |
|---|
| 05/26/2005 | WO2005047531A1 Assay for pkc-beta activation of phosphorylation of myosin heavy chain polypeptide |
| 05/26/2005 | WO2005047514A1 Proteins involved in signal transduction |
| 05/26/2005 | WO2005047511A2 Bacterial expression of protease inhibitors and variants thereof |
| 05/26/2005 | WO2005047478A2 Compositions and methods for regulation of tumor necrosis factor-alpha |
| 05/26/2005 | WO2005047476A2 Inhibition of retroviral replication through modulation of the host cell ubiquitylation |
| 05/26/2005 | WO2005047459A2 Sars nucleic acids, proteins, antibodies, and uses thereof |
| 05/26/2005 | WO2005047455A2 Methods for the production of apolipoproteins in transgenic plants |
| 05/26/2005 | WO2005047338A1 Cancer cell targeting gene delivery method |
| 05/26/2005 | WO2005047326A2 Interleukin-10 antibodies |
| 05/26/2005 | WO2005047323A1 Dry recombinant human alpha 1-antitrypsin formulation |
| 05/26/2005 | WO2005047322A2 Factor viii compositions and methods |
| 05/26/2005 | WO2005047320A2 Equine p-selection glycoprotein ligand-1 and uses thereof |
| 05/26/2005 | WO2005047319A2 Dna sequence and expressed recombinant glycoproteins related to feline thyrotropin |
| 05/26/2005 | WO2005047316A2 Insulin releasing peptides |
| 05/26/2005 | WO2005047314A2 Fgf-beta binding and supported peptides |
| 05/26/2005 | WO2005047313A1 Peptide or protein capable of binding lipid a and lps, dna coding for the peptide or protein, and utilizing the peptide or protein, lps adsorbent or lps poison neutralizer |
| 05/26/2005 | WO2005047312A1 Beauveriolide derivative |
| 05/26/2005 | WO2005046798A1 Treatment of bone loss utilizing full length parathyroid hormone |
| 05/26/2005 | WO2005046747A2 Intravascular devices and fibrosis-inducing agents |
| 05/26/2005 | WO2005046746A2 Medical implants and fibrosis-inducing agents |
| 05/26/2005 | WO2005046732A2 Methods and compositions for the inhibition of hiv-1 replication |
| 05/26/2005 | WO2005046721A2 Compositions for reducing bacterial carriage and cns invasion and methods of using same |
| 05/26/2005 | WO2005046720A2 Diagnosis, prognosis and treatment of pulmonary diseases using foxa2 |
| 05/26/2005 | WO2005046719A1 Vaccine and method for treatment of neurodegenerative diseases |
| 05/26/2005 | WO2005046718A1 Diagnosis and hyperinsulinemia and type ii diabetes and protection against same based on genes differentially expressed in pancreas cells (12.1) |
| 05/26/2005 | WO2005046717A1 Use of hyperpolymer haemoglobin for treating a pulmonary oedema |
| 05/26/2005 | WO2005046716A1 Soluble pharmaceutical compositions for parenteral administration comprising a glp-1 peptide and a insulin peptide of short time action for treatment of diabetes and bulimia |
| 05/26/2005 | WO2005046715A1 Physiologically active complex |
| 05/26/2005 | WO2005046714A2 Cytokine antagonist molecules |
| 05/26/2005 | WO2005046713A1 Proteins involved in quorum sensing |
| 05/26/2005 | WO2005046712A1 Hepatitis c virus inhibitors |
| 05/26/2005 | WO2005046711A2 Stimulation or inhibition of gamma delta t-cells to promote or inhibit bone healing |
| 05/26/2005 | WO2005046710A2 Tgf-beta binding and supported peptides |
| 05/26/2005 | WO2005046709A2 Tgf - beta binding and supported peptides |
| 05/26/2005 | WO2005046708A1 Selective inhibitors of nuclear factor-kb activation and uses thereof |
| 05/26/2005 | WO2005046707A1 Pharmaceutical compositions including low dosages of desmopressin |
| 05/26/2005 | WO2005046704A1 Pharmaceutical product comprising tissue of the male vegetal reproductive system |
| 05/26/2005 | WO2005046703A1 Use of strain of bacillus and byproducts thereof for inhibiting formation of blood vessels |
| 05/26/2005 | WO2005046691A1 Combination of a farnesyl tranferase inhibitor with an antihormonal agent for the treatment of breast cancer |
| 05/26/2005 | WO2005046660A1 MODULATING SUBSTANCES OF THE NITRIC OXID (NO) - CYCLIC GUANOSINE - 3’,5’- MONOPHOSPHATE (cGMP) SIGNALING PATHWAY FOR THE TREATMENT OF DENTAL DISORDERS |
| 05/26/2005 | WO2005046646A2 Blister pack and solid dosage form comprising desmopressin |
| 05/26/2005 | WO2005046645A1 Microparticles comprising somatostatin analogues |
| 05/26/2005 | WO2005046642A1 Compositions of lipids and cationic peptides |
| 05/26/2005 | WO2005046623A1 Combined cosmetic or therapeutic preparation |
| 05/26/2005 | WO2005046610A2 Genes differentially expressed by acutely isolated resident progenitor cells of the human white matter |
| 05/26/2005 | WO2005046594A2 Methods of using and compositions comprising a jnk inhibitor for the treatment and management of asbestos-related diseases and disorders |
| 05/26/2005 | WO2005046592A2 Methods of using and compositions comprising pde4 modulators for the treatment and management of asbestos-related diseases and disorders |
| 05/26/2005 | WO2005046587A2 Preparation and composition of inter-alpha inhibitor proteins from human plasma for therapeutic use |
| 05/26/2005 | WO2005046571A2 Lactoferrin as an adjuvant in cancer vaccines |
| 05/26/2005 | WO2005046569A2 Pharmaceutical compositions for the treatment of sars |
| 05/26/2005 | WO2005046516A2 Medical implants and anti-scarring agents |
| 05/26/2005 | WO2005046454A2 Methods of using gelsolin to treat or prevent bacterial sepsis |
| 05/26/2005 | WO2005046318A2 Methods of using and compositions comprising immunomodulatory compounds for the treatment and management of asbestos-related diseases and disorders |
| 05/26/2005 | WO2005025624A3 The use of eukaryotic genes affecting cell cycle control or cell cycle progression for diagnosis and treatment of proliferattive diseases |
| 05/26/2005 | WO2005023845A3 Cyclic peptides acting as urotensin-ii antagonists |
| 05/26/2005 | WO2005016368A3 Use of phosphophoryn for inducing biomineralization and bone regeneration |
| 05/26/2005 | WO2005014642A3 Novel multifunctional cytokines |
| 05/26/2005 | WO2005012336A3 Uranium-chelating peptides and uses thereof |
| 05/26/2005 | WO2005009456A3 Use of peptidic conjugates for preparing compositions for alopecia preventive and curative treatment |
| 05/26/2005 | WO2005009363A3 Treatment of pre-cancerous conditions and prevention of cancer using pcdgf-based therapies |
| 05/26/2005 | WO2005009217A3 Diagnosis of pre-cancerous conditions using pcdgf agents |
| 05/26/2005 | WO2005004899A3 Biologically active substance of a vasoactive intestinal peptide for treating interstitial lung infections |
| 05/26/2005 | WO2004110416A3 Use of a cx3c agonist for the treatment of pain and for promoting nerve regeneration |
| 05/26/2005 | WO2004103294A3 Methods and compositions for the prevention and treatment of sepsis |
| 05/26/2005 | WO2004100987A3 Methods of using il-1 antagonists to treat neointimal hyperplasia |
| 05/26/2005 | WO2004099784A3 Method for determining a tissue degradation process by detection of fibromodulin neoepitopes |
| 05/26/2005 | WO2004096826A3 Method for selective inhibition of human n-myc gene in n-myc expressing tumors through antisense and antigen peptido-nucleic acids (pna) |
| 05/26/2005 | WO2004080412A3 Paclitaxel hybrid derivatives |
| 05/26/2005 | WO2004046326A3 Modulation of interleukin 22 receptor expression |
| 05/26/2005 | WO2004042068A3 Injectable and bioadhesive polymeric hydrogels as well as related methods of enzymatic preparation |
| 05/26/2005 | WO2002093998A9 Suppression of allergic reactions by transdermal administration of allergens in conjunction with or conjugated to toxin subunits or fragments thereof |
| 05/26/2005 | US20050114914 linker for activation of T- cells (lat genes and proteins), used for screening drug useful for treatment against asthma and allergies |
| 05/26/2005 | US20050113903 Medical device for delivering biologically active material |
| 05/26/2005 | US20050113627 comprising tris(hydroxymethyl)aminomethane, urea, beta-cyclodextrin and reduced glutathione; for absorbing hydrogen sulfide and carbon dioxide from the air |
| 05/26/2005 | US20050113577 Such as hydrochloride salt 3-[5-(4-methanesulfonyl-piperazin-1-yl-methyl)-1H-indol-2-yl]-1H-quinolin-2-one; signal transduction; for treatment of angiogenesis, cancer, tumor growth, atherosclerosis, age related macular degeneration, diabetic retinopathy, and inflammatory diseases |
| 05/26/2005 | US20050113565 Pegylated factor VII glycoforms |
| 05/26/2005 | US20050113561 Hydrochloride salts of a glycopeptide phosphonate derivative |
| 05/26/2005 | US20050113408 Susceptibility gene for myocardial infarction, stroke, and PAOD; methods of treatment |
| 05/26/2005 | US20050113329 Contacing cell/body fluid with antibody which binds human aspartyl (asparaginyl) beta-hydroxylase (HAAH) polypeptide; for inhibiting tumor growth; gene expression inhibition; immunization |
| 05/26/2005 | US20050113327 Administering by direct infusion to a colon cancer or melanoma native RNase B1 isolated from Aspergillus niger; reducing tumor number or size of colon cancer or melanoma |
| 05/26/2005 | US20050113323 Introducing antisense nucleotides which are complementary to untranslated region of prostate tumor inducing gene |
| 05/26/2005 | US20050113322 Oligonucleotides which hybridize to inhibit expression; nucleosides; chimera; colloids; cardiovascular disorders; nervous system disorders; diabetes; ischemia/reperfusion injuries |
| 05/26/2005 | US20050113311 Comprises N-alpha-acetyl-L-histidine; kits; droppers |
| 05/26/2005 | US20050113310 Use of inhibitors of enzymes having activities of amino peptidase N and/or dipeptidyl peptidase IV and of pharmaceutical preparations thereof for a therapy and prevention of chronical neurodegenerative diseases |
| 05/26/2005 | US20050113309 Useful as thrombin inhibitors |
| 05/26/2005 | US20050113308 Pentapetide containing a proline amino acid; cytotoxic agent |
| 05/26/2005 | US20050113305 Enhancing the efficacy of chemotherapy and/or radiotherapy by administering a specific inhibitory peptide, preferably before the therapy |
| 05/26/2005 | US20050113304 Recombinant expression system for production of a peptide capable of inhibiting the protease activity of Botulinum toxin B or tetanus toxin which expression system comprises a nucleotide sequence encoding the peptide operably linked to a control sequence for effecting expression |
| 05/26/2005 | US20050113303 Method for treating metabolic bone disease such as osteomalacia and osteoporosis in a patient by administering a compound that modulates phosphate regulating endopeptidase homolog (PEX) expression and/or PEX enzymatic activity |
| 05/26/2005 | US20050113302 Cardioprotective protein (A3P) or A3 receptor-mediated cardioprotective protein isoform (A3PI) exhibiting an altered expression in cardiac tissue in response to exposure to an A3 agonist; useful for clinical screening, diagnosis, prognosis, therapy, and prophylaxis |
| 05/26/2005 | US20050113301 Administering calcitonin and dehydroepiandrosterone (DHEA) to patient being treated for systemic lupus erythematosus where the immunosuppressant tends to reduce bone mineral density(BMD); osteoporosis |
| 05/26/2005 | US20050113299 Protein a compositions and methods of use |
| 05/26/2005 | US20050113298 Receptor binding peptides derived from the SARS S protein |
| 05/26/2005 | US20050113297 Contacting target cell or noncellular molecular entity with phagocytic marker and moiety that binds to a component that is present on or at surface of target cell or noncellular molecular entity, thereby increasing level or density of phagocytic marker on target cell; marker comprises phosphatidylserine |
| 05/26/2005 | US20050113295 Carboxamide and amino derivatives and methods of their use |
| 05/26/2005 | US20050113294 Carboxamide and amino derivatives and methods of their use |
| 05/26/2005 | US20050113293 Cyclic and linear oligopeptides; capable of increasing gap junction conductance; lack the proarrhythmic side effects; use as drug to also treat eye disorders, cancer, and gastrointestinal disorders among others |
| 05/26/2005 | US20050113292 Protein mimetic for preventing HIV-1 entry to host cells of living subject through membrane fusion, wherein HIV-1 contains envelope glycoprotein gp41 that has plurality of peptides in pre-hairpin state, comprising at least two monomeric peptide strands and interstrand linker coupling peptide strands |
| 05/26/2005 | US20050113291 Use of a substance which binds to and initiates signaling of the human SARP-1 receptor or a substance which stimulates release or potentiates the activity of endogenous SARP-1 for the manufacture of a medicament for the treatment and/or prevention of scleroderma, in particular of systemic sclerosis |
| 05/26/2005 | US20050113290 Method and composition for treating cancer by converting soluble radioactive toxic agents into insoluble radioactive toxic precipitates via the action of non-mammalian enzymes bound to the non-endocytosing receptors of target cells |